Most cancer genome studies have focused on mutations in the tumor itself and how such gene variants allow a tumor to grow unchecked.

Revenue and Sales Performance: For the fiscal third quarter of 2025, Biomerica reported net sales of $1.10 million, a 10% increase from $1.00 million recorded in the same quarter of the previous year.

Galmed Pharmaceuticals Ltd. ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company dedicated to developing novel treatments for liver, cardiometabolic, and gastrointestinal oncology ...